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Abstract
Purpose:  We  report  the  results  of  combining  cardiac  and  hepatic  MRI  in  the  same  examination  to
monitor 48  multi-transfused  patients  presenting  iron  overload  secondary  to  their  transfusions.
This cardiac  MRI  technique  uses  acquisition  sequences  and  calculation  software  that  are  readily
available  for  1.5  T  systems,  and  it  has  been  validated  to  screen  for  patients  at  risk  of  cardiac
complications  who  present  myocardial  iron  overload  (T2*  <  20  milliseconds).
Patients and  methods:  A  total  of  176  combined  MRI  examinations  were  performed  between  May
2006 and  January  2012  in  48  patients  who  had  received  transfusions  due  to  thalassaemia.  This
monocentric  retrospective  study  brings  together  all  of  the  imaging  examinations  carried  out.
Results: There  was  a  positive  correlation  between  the  cardiac  T2*  values  and  left  ventricular
ejection fraction,  which  were  measured  in  the  same  examination.  At  the  ﬁrst  assessment  23/48
patients had  a  T2*  <  20  ms.  These  patients  showed  a  signiﬁcant  improvement  in  cardiac  T2*  over
time while  their  iron  chelation  therapy  was  being  intensiﬁed.
Abbreviations: MRI, magnetic resonance imaging; LVEF, left ventricular ejection fraction; RT, relaxation time; ET, excitation time; ms,
milliseconds.
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Conclusion:  This  study  validates  the  application  of  the  cardiac  MRI  technique  used  to  monitor
cardiac iron  overload  in  patients  who  have  undergone  multiple  transfusions.
© 2014  Published  by  Elsevier  Masson  SAS  on  behalf  of  the  Éditions  françaises  de  radiologie.
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halassaemia  major  is  a  form  of  anaemia  requiring  monthly
ransfusions  from  early  childhood,  with  each  RBC  introduc-
ng  200  mg  of  iron  to  the  patient’s  system  that  they  lack
he  natural  mechanism  to  eliminate.  In  spite  of  iron  chela-
ion  therapy,  heart  failure  secondary  to  post-transfusion  iron
verload  remains  the  leading  cause  of  death  in  this  illness
1—3].
The  MRI  techniques  that  are  used  to  detect  and  quan-
ify  iron  in  the  tissues  allow  the  concentrations  of  hepatic
nd  cardiac  iron  to  be  assessed.  Pennell  et  al.  described
 reproducible  method  for  quantifying  myocardial  iron
oncentration  using  T2*  sequences  [4].  A  T2*  value  of  below
0  milliseconds  points  to  myocardial  iron  overload.  If  cardiac
ron  overload  is  detected,  patients  at  risk  of  heart  failure  can
e  identiﬁed  before  they  become  symptomatic  [5,6].
In  France,  for  several  years  radiologists  have  been  using
 standardised  and  validated  method  to  assess  hepatic  iron
verload,  to  which  a  speciﬁc  myocardial  T2*  sequence  was
dded  to  allow  an  overall  assessment  of  hepatic  and  myocar-
ial  iron  overload  in  a  single  examination  [7].  This  technique
as  been  validated  to  screen  for  patients  who  show  a  T2*
alue  below  20  ms  [8].
We  report  here  an  exhaustive  experience  of  monitoring
sing  this  combined  hepatic  and  cardiac  MRI  technique  for
atients  treated  in  Marseille  at  the  thalassaemia  reference
entre.
atients and methods
his  was  a  monocentric  retrospective  study  of  48  multi-
ransfused  patients  with  thalassaemia  major  (n  =  41)  or
halassaemia  intermedia  (n  =  7)  who  underwent  in  total  179
ardiac  MRI  scans  between  May  2006  and  January  2012,  176
f  which  were  combined  with  hepatic  MRI.  This  study  was
xhaustive  because  it  included  all  of  the  imaging  studies
erformed  in  patients  with  thalassaemia  monitored  at  the
pecialist  thalassaemia  reference  centre  in  Marseille  over
he  relevant  period.
There  were  21  men  and  27  women  with  a  mean  age  of
4  ±  10.4  years  at  the  time  of  their  ﬁrst  cardiac  MRI.  All
f  the  MRI  scans  were  performed  in  the  radiology  depart-
ent  of  La  Timone  Hospital  in  Marseille.  At  the  time  of
heir  ﬁrst  cardiac  MRI,  45  patients  out  of  48  were  receiv-
ng  iron  chelation  therapy.  A  result  of  T2*  <  20  ms  routinely
rompted  consideration  of  intensifying  the  iron  chelation
herapy  (increasing  doses  or  introducing  combination  ther-
py).The  patients  underwent  combined  cardiac  MRI  using  a
.5  Tesla  system  (1.5  T  Whole-body  MR  scanner,  Symphony
IM,  Siemens  with  a  dedicated  12-element  coil  and  1.5
 Achieva  Philips  with  a  dedicated  5-element  coil).  The
e
o
i
amages  were  acquired  with  electrocardiogram  synchronisa-
ion  during  breath  hold  and  expiration  with  patients  lying
n  their  backs.  Three  successive  sequences  were  carried
ut:  T1-weighted  spin-echo  morphological  sequences,  cine
equences,  and  gradient-echo  sequences  to  calculate  T2*-
eighting.  To  calculate  left  ventricular  ejection  fraction  we
sed  balanced  gradient-echo  cine  sequences  or  Steady  State
ree  Precession  (SSFP):  RT/ET  =  3.2  ms/1.8  ms,  7  mm  slice
hickness,  no  spacing  between  slices,  an  angle  of  50◦,  spa-
ial  resolution  of  2.1  ×  1.6  ×  7  mm,  temporal  resolution  of
5  ms;  then  for  post-treatment,  specialist  semi-automatic
easuring  software  (Argus  Viewer).  We  used  the  method
escribed  by  the  Lille  team  [7].  Three  acquisitions  were
aken  with  slices  10  mm  thick  through  the  short  axis  of
he  heart  using  prospective  ECG  synchronisation,  a  res-
lution  of  1.4  ×  1.4  mm,  a  ﬁeld  of  view  of  350  mm,  a
andwidth  of  810  Hz,  a  spatial  resolution  of  256  ×  256,
 ﬂip  angle  of  20◦, and  the  number  of  excitations  per
ycle  was  10.  We  used  the  following  parameters:  RT/ET-
T:  386  ms/2.5  ms—5  ms,  RT/ET-ET:  426  ms/2.5  ms—10  ms
nd  RT/ET-ET:  377  ms/2.5  ms—20  ms  (Siemens)  and  RT/ET-
T:  8  ms/2.5  ms—5  ms,  RT/ET-ET:  13  ms/2.5  ms—10  ms  and
T/ET-ET:  23  ms/2.5  ms—20  ms  (Philips).
The  signal  of  the  images  obtained  was  analysed  at  the
eﬁned  region  of  interest  (ROI)  at  the  interventricular
eptum.  The  T2*  value  was  calculated  by  measuring  the  rela-
ionship  between  these  echoes  using  the  following  formula:
2*  =  (ET2  −  ET1)/Log  (S1/S2).
To  calculate  the  liver  iron  concentration,  we  used  the
ethod  described  by  Gandon  et  al.  plus  an  additional
equence  that  allowed  major  hepatic  iron  overloads  to  be
uantiﬁed  [9,10].  The  six  following  liver  sequences  were
arried  out:
1 RT:  120  ms;  ET  21  ms;  angle  20◦;
2  RT:  120  ms;  ET  14  ms;  angle  20◦;
3  RT:  120  ms;  ET  9  ms;  angle  20◦;
4  RT:  120  ms;  ET  4  ms;  angle  20◦;
5  RT:  120  ms;  ET  4  ms;  angle  90◦;
6  RT:  48  ms;  ET  1.8  ms;  angle  60◦.
Then  a  comparison  was  made  between  the  liver  ROI  and
he  paravertebral  muscles  using  the  software  available  on
he  website  of  the  University  of  Rennes  [9].
For  the  statistical  analysis  the  connections  between  the
ardiac  T2*  data  and  both  the  left  ventricular  ejection  frac-
ion  (LVEF)  and  the  hepatic  iron  levels  on  MRI  were  studied
sing  Spearman’s  correlation  coefﬁcient.  The  LVEF  values
y  patient  group,  those  who  did  or  did  not  have  myocardial
ron  overload,  deﬁned  as  T2*  ≥  20  ms,  were  compared  using
 non-parametric  test  (Mann-Whitney  test).  A  mixed  linear
ffect  model  was  used  to  study  the  change  in  T2*  values
ver  time.  A  random  intercept  model  was  used  to  allow  for
ndividual  variability.  Two-tailed  statistical  tests  were  used
nd  P-values  ≤  0.05  were  considered  to  be  signiﬁcant.  The
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Table  1  Comparison  of  the  medians  of  LVEF  in  %
depending  on  whether  patients  have  a  T2*  <  20  ms  (20
patients)  or  a  T2*  ≥  20  ms  (24  patients).
T2*  (ms) Number  of
patients
LVEF (%)  P
<  20 20  57.6  (43.0—77.0)
≥  20 24  62.4  (48.0—74.2) 0.002
LVEF: left ventricular ejection fraction; ms: milliseconds.
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analysis  was  carried  out  using  the  software  R,  version  2.14.0
[10].
Results
In  48  patients  managed  at  the  centre,  179  cardiac  MRI  scans
including  an  assessment  of  T2*  were  carried  out,  176  of
which  were  combined  with  an  assessment  of  liver  iron.  Over
a  68-month  period,  the  48  patients  each  had  a  mean  of  3.7
cardiac  MRI  scans.  The  time  between  the  ﬁrst  and  the  last
imaging  examination  was  on  average  4  years  and  5  months.
LVEF  was  only  calculated  in  103  examinations  (46  patients)
and  this  was  a  random  outcome,  based  on  the  availability
and  quality  of  the  sequences  taken.
Mean  cardiac  T2*  at  the  ﬁrst  examination  was
21.2  ±  10.1  ms  and  mean  LVEF  was  59.64  ±  7.15%.  Mean
hepatic  iron  concentration  was  280  ±  114  mol/g  dry  liver.
We  found  a  positive  correlation  between  the  ﬁrst  LVEF
and  corresponding  cardiac  T2*  in  the  44  patients  analysed
using  Spearman’s  correlation  coefﬁcient  with  a  value  of  0.40
(conﬁdence  interval  [CI]  95%:  0.06;  0.63;  P  <  0.01,  Fig.  1)
which  supports  a  link  between  an  increased  T2*  value  and
an  increased  LVEF.
Furthermore,  the  left  ventricular  ejection  fraction  values
in  the  sub-group  of  20  patients  who  had  a  T2*  < 20  ms  were
signiﬁcantly  lower  than  those  of  the  24  patients  with  normal
T2*:  57.6%  as  against  62.4%  (P  =  0.002,  Table  1).
Of  the  48  patients,  23  had  a  cardiac  T2*  <  20  ms  at  their
ﬁrst  MRI.  Iron  chelation  therapy  was  adjusted  for  18  of
these:  combination  therapy  was  introduced  for  ten  patients,
nine  of  which  were  regimens  combining  DEFERIPRONE  and
DEFEROXAMINE,  while  an  increased  dose  of  the  chelating
agent  used  as  monotherapy  was  given  to  six  patients,  and
for  two  patients,  a  change  was  made  to  the  agent  used  as
monotherapy.  In  ﬁve  cases  in  which  T2*  was  only  slightly
low  (between  17.5  and  19.5  ms)  there  was  no  change  to
Figure 1. Correlation between the T2* value in ms and the left
ventricular ejection fraction in % at inclusion in 44 patients. The
correlation coefﬁcient was assessed at 0.396 (0.06—0.627), P < 0.01.
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sreatment.  Over  the  course  of  their  monitoring,  a  further
ix  patients  presented  T2*  <  20  ms:  three  patients  had  their
reatment  intensiﬁed  through  combination  therapy,  and  the
ther  three  presented  only  very  modest  T2*  decreases.  No
atients  were  lost  to  follow-up,  deceased,  or  developed
eart  failure  during  the  study  period.
An  analysis  of  the  change  in  T2*  values  over  time  showed
 signiﬁcant  improvement  in  T2*  in  the  sub-group  of  patients
hose  T2*  was  <  20  ms  at  their  ﬁrst  cardiac  MRI  based  on  a
egression  coefﬁcient  of  0.23  (CI  95%:  0.17;  0.28;  P  <  0.0001,
able  2).  A signiﬁcant  reduction  in  liver  iron  concentration
ver  time  was  demonstrated  with  a  regression  coefﬁcient  of
1.23  (CI  95%:  −2.37;  −0.10;  P <  0.0001).
In  line  with  what  is  normally  reported  in  iron  overloaded
ubjects  receiving  long-term  iron  chelation  therapy,  no  cor-
elation  was  seen  between  the  iron  levels  in  the  heart  and
iver.
iscussion
ince  1999,  a  cardiac  MRI  technique  developed  by  Pennell
nd  Anderson’s  team  at  the  Royal  Brompton  Hospital  in  Lon-
on  has  been  available  that  makes  use  of  T2*  to  achieve  a
on-invasive  method  for  quantifying  myocardial  iron  over-
oad.  This  technique  has  become  the  gold  standard  for
etecting  myocardial  iron  overload  using  speciﬁc  sequences
nd  post-treatment  software  [4]. This  measure  is  also  cor-
elated  to  left  ventricular  ejection  fraction  [6,11—17].  It
redicts  development  of  heart  failure  in  the  short-term
t  the  pre-symptomatic  stage,  which  means  that  preven-
ive  iron  chelation  therapy  can  be  adjusted  [6,12], and  it
epresents  a major  step  forward  in  the  management  of  post-
ransfusion  iron  overload.
In France,  an  MRI  technique  that  combines  cardiac
equences  to  calculate  T2*  and  left  ventricular  ejection  frac-
ion  with  liver  sequences  in  the  same  examination,  allowing
iver  iron  overload  to  be  calculated,  is  widely  used.  To
alculate  iron  excess,  we  use  a  number  of  gradient-echo
equences  of  the  heart  and  liver  and  balanced  gradient-
cho  cine  sequences  to  measure  left  ventricular  systolic
unction  [7—10,18].  The  method  is  straightforward,  readily
vailable,  and  standardised.  It  makes  patient  monitoring
asier  because  it  entails  only  a  single  examination  to  quan-
ify  both  myocardial  and  liver  iron,  as  well  as  assessing
eft  ventricular  ejection  fraction.  The  cardiac  T2*  sequence
as  been  validated  to  screen  for  iron  overload  because  it
dentiﬁes  with  good  speciﬁcity  and  sensitivity  patients  pre-
enting  T2*  <  20  ms  based  on  the  standard  technique  used  by
1068  A.  Quatre  et  al.
Table  2  Change  in  T2*  values  over  time  in  24  patients  with  a T2*  <  20  ms  and  24  patients  with  a  T2*  ≥  20  ms.
T2*  (ms)  Number  of  patients  Correlation  coefﬁcient  P
All  patients  48  −0.01  (−0.08;  0.03)  0.71
≥  20  25  −0.01  (−0.10;  0.07)  0.77
<  20  23  0.22  (0.17;  0.28)  <  0.0001
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[ms: milliseconds.
nderson  and  Pennell  et  al.  [5].  In  this  study,  we  also  show
 correlation  between  left  ventricular  ejection  fraction  and
he  cardiac  T2*  value.
An  improvement  over  time  in  patients  presenting  myocar-
ial  iron  overload  after  intensiﬁed  iron  chelation  therapy
as  been  reported  in  controlled  studies  [19,20].  In  our
tudy,  an  initial  T2*  value  below  20  ms  led  to  adjusted  iron
helation  therapy  in  18  cases,  with  the  ﬁve  other  patients
resenting  T2*  values  only  very  slightly  below  20  ms.  Along-
ide  intensiﬁcation  of  iron  chelation  therapy,  the  cardiac  MRI
esults  improved  and  no  new  case  of  heart  failure  arose.
his  improvement  is  only  statistically  signiﬁcant  for  the
ub-group  of  patients  whose  T2*  <  20  ms,  i.e.  the  group  of
nterest,  since  only  these  patients  are  at  risk  of  developing
eart  failure  in  the  short-term.  The  French  technique  used
o  measure  T2*  can  be  used  with  various  different  software
rograms  and  systems;  it  has  demonstrated  excellent  values
or  sensitivity,  speciﬁcity,  and  positive  and  negative  predic-
ive  values  for  the  detection  of  T2*  <  20  ms  when  compared
o  the  standard  technique.  It  enables  not  only  screening  but
lso  monitoring  of  patients  at  risk  of  heart  failure  after  their
reatment  has  been  adjusted.
This  technique  is  not  validated  for  monitoring  patients
ith  normal  T2*:  here  we  must  note  that  greater  error  in
easuring  T2*  values  exceeding  20  ms  in  comparison  to  the
tandard  technique  has  already  been  reported  (standard
eviation  10.45  ms)  [8].
Finally,  we  observed  a  signiﬁcant  reduction  in  liver  iron
oncentration  over  time  for  the  entire  cohort.
The  limitations  of  our  study  were  that  it  was  at  a  single
entre  and  it  was  retrospective  as  well  as  the  variation  in
ength  of  time  between  the  MRI  scans  carried  out.  However,
n  showing  the  improvement  over  time  of  the  cardiac  MRI
ndices,  the  study  validates  the  current  practice  of  using
he  cardiac  sequence  of  the  combined  MRI  to  adjust  iron
helation  therapy  in  patients  with  cardiac  iron  overload.
onclusion
 cardiac  MRI  combined  with  liver  exploration  to  assess  iron
verload  offers,  through  its  speciﬁc  cardiac  T2*  sequence,
ffective  monitoring  for  patients  with  thalassaemia  who
resent  post-transfusion  cardiac  iron  overload.isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.eferences
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